Core Insights - VIAVI Solutions Inc. has launched its second-generation RSR Transcoder, designed to enhance operational capabilities in GPS/GNSS-denied environments [1][2] - The RSR Transcoder provides assured Position, Navigation, and Timing (PNT) outputs, facilitating upgrades to legacy systems [2][4] - The product addresses the increasing threat of GPS and GNSS jamming and spoofing, which are becoming common in electronic warfare [3][6] Product Features - The RSR Transcoder includes a GPS full constellation simulator and utilizes a patented algorithm for rapid conversion of assured inputs to Universal GPS signals [4] - It is ruggedized with IP68 enclosures suitable for various platforms and operates in a covert mode [5] - The device outputs at 100 Hz and offers multiple holdover oscillator options [5] Industry Context - The reliance on PNT technologies in modern military systems is growing, with adversaries increasingly capable of disrupting these systems [6] - The RSR Transcoder is positioned as a cost-effective solution for upgrading legacy systems to withstand such disruptions [6] Event Participation - The RSR Transcoder will be showcased at the 2025 Joint Navigation Conference, highlighting its capabilities in D3SOE navigation [6] - VIAVI will also present on various topics related to navigation and anti-jamming technologies during the conference [8]

ADTRAN Holdings, Inc. (ADTN) has unveiled its latest Positioning, Navigation and Timing (PNT) solution, the OSA aPNT+ platform, at Jammertest 2024 in Norway. The platform integrates various PNT sources, including Iridium Satellite Time and Location (STL) services to effectively reduce risks and set new standards for securing applications in the public and private sectors. Adtran's Oscilloquartz aPNT+ solution utilizes a multi-layered strategy that includes advanced Global Navigation Satellite Systems (GNSS) ...

Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from ______to ______. Commission file number: 001-39311 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) (State or oth ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ______to ______. Commission file number: 001-39311 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (IRS Employer Identification No.) incorporation or organization) 4850 West 78th Street Indianapolis, IN 46268 (Address of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ______to ______. Commission file number: 001-39311 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) (State or other j ...

Financial Performance - POINT reported a net loss of $45.9 million for the year ended December 31, 2021, and a net income of $98.3 million for the year ended December 31, 2022[188]. - As of December 31, 2022, POINT had cash, cash equivalents, and investments totaling $541.3 million, with accumulated earnings of $39.0 million[193]. - POINT expects to incur significant losses for the foreseeable future due to ongoing research and development efforts, including clinical trials for its lead product candidates[188][192]. - The company anticipates that its existing cash resources will fund its operating expenses and capital expenditure requirements into 2026[200]. - POINT's operations have consumed substantial amounts of cash since inception, highlighting the need for additional financing to support ongoing development efforts[193][199]. Product Development and Clinical Trials - POINT is in the early stages of product development and has no products licensed for commercial sale, which poses significant risks to its financial condition[187][205]. - The company has entered into an agreement with Lantheus for exclusive worldwide licenses to commercialize Lu-PNT2002 and Lu-PNT2003, indicating a strategic partnership for product development[210]. - POINT's clinical trials may face delays or failures, which could significantly impact its ability to commercialize its product candidates[213]. - The acceptance of POINT's product candidates by the medical community and patients is crucial for market success[224]. - Regulatory approval delays could significantly impact POINT's ability to commercialize its product candidates[226]. - POINT's ability to demonstrate safety and efficacy is essential for obtaining regulatory approval[227]. - The results of preclinical studies and early-stage clinical trials may not predict future outcomes, posing risks to product development[238]. - POINT's clinical trials may face setbacks similar to those experienced by other pharmaceutical companies, affecting business operations[239]. - The ongoing trials of Lu-PNT2002 and Lu-PNT2003 are open-label trials, and interim data may change as more participant data becomes available[240]. - POINT's clinical trials may be adversely affected by the COVID-19 pandemic, including delays in participant enrollment and clinical site initiation[259]. Regulatory and Compliance Challenges - POINT has never commercialized a product candidate and may face delays in obtaining regulatory approval for its current and future product candidates[242]. - POINT's ability to obtain regulatory approval may be compromised if interim data differs from actual results or if regulatory authorities disagree with its conclusions[241]. - The company may need to conduct additional costly clinical trials if the FDA requires further studies before reconsidering its applications[242]. - Regulatory compliance in international markets is critical; failure to comply could reduce POINT's target market and harm its market potential[326]. - Even with FDA approval, POINT may face ongoing regulatory obligations that could result in additional expenses and penalties for non-compliance[327]. - Changes in government regulations, such as those from the Biden administration, could impact POINT's business and regulatory approval processes[328]. Market and Competitive Landscape - POINT faces significant competition from larger pharmaceutical companies with greater resources, which may hinder its market opportunities[276]. - The market opportunities for POINT's product candidates may be smaller than anticipated, potentially limiting the patient population eligible for treatment[258]. - POINT's product candidates must gain acceptance as cost-effective alternatives to competing products to achieve commercial success[224]. - POINT's ability to generate revenue from product sales will depend on the effectiveness of Lantheus and other third parties' marketing efforts, which may be less successful than in-house commercialization[269]. Manufacturing and Supply Chain - The manufacturing of POINT's product candidates is complex and highly regulated, with a facility constructed in Indianapolis, Indiana, to produce approved drugs[281]. - POINT may need to scale up production significantly to meet anticipated market demand, which involves additional research, investment, and regulatory approvals[283]. - Any delays in regulatory approvals for POINT's manufacturing facilities could adversely affect its development plans and commercialization efforts[284]. - Quality control failures during production could lead to significant disruptions and negatively impact POINT's business and financial results[288]. - POINT's current suppliers of n.c.a. Lu are located in Germany and Israel, and any shipping interruptions could impact clinical trials[294]. - POINT believes there is sufficient supply of radioisotopes to support ongoing clinical trials, but plans to establish redundant suppliers before commercialization[294]. Intellectual Property and Legal Risks - POINT's ability to protect its intellectual property is critical, as failure to maintain patent protection could allow competitors to commercialize similar products[361]. - The patent prosecution process is complex and costly, and POINT may not be able to secure necessary patents in a timely manner[363]. - POINT's existing and future intellectual property license agreements impose various obligations, and failure to comply could result in termination of licenses[366]. - POINT is subject to U.S. and foreign anti-corruption laws, and violations could lead to substantial penalties and reputational damage[359]. - Cybersecurity risks are increasing, and unauthorized access to sensitive data could result in significant liabilities and operational disruptions[353]. Collaboration and Partnerships - POINT's collaboration with Lantheus for the commercialization of Lu-PNT2002 and Lu-PNT2003 is critical, and any failure in this partnership could limit market potential[300]. - The company faces significant competition in establishing strategic partnerships, which may delay development and commercialization efforts[302]. - POINT's reliance on third-party collaborators for clinical trials introduces risks related to control over trial execution and data reliability[296]. - Any delays in entering new collaborations could adversely affect the development timelines and financial condition of POINT[305]. - Collaborators may not commit sufficient resources to marketing and distribution, potentially impacting the success of POINT's product candidates[307]. Environmental and Compliance Costs - POINT may incur significant costs related to compliance with environmental, health, and safety laws, which could materially affect its business success[306]. - Compliance with environmental regulations is currently not significant in cost, but future regulations could impair research and production efforts[309]. - Investigations into compliance with healthcare laws can divert management's attention and increase operational costs[343].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ______to ______. Commission file number: 001-39311 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware 85-0 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ______to ______. Commission file number: 001-39311 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware 85-080049 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ______to ______. Commission file number: 001-39311 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) (State or other j ...

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Washington, D.C. 20549 FORM 10-K Commission File Number 001-39311 POINT BIOPHARMA GLOBAL INC. (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 4850 West 78th Street, Indianapolis, IN 46268 (647) 812-2417 (Address, including zip ...